SEC Form 4 · accession 0000899243-18-007935
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John McDonough
Officer — President & CEO · Director
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Restricted Stock UnitsF1 | — | Mar 15, 2018 | A | 434,783 | A | — | Mar 15, 2021 | Common Stock | 434,783 | 434,783 | D |
Explanation of responses
- F1Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the achievement of certain pre-established 90-day average daily closing prices per share goals over a three-year performance period.